TTNP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	10 646.00
平均成交量	10 780.00
市值	6.48M
EPS	$0 ( 2024-04-02 )
下一个收益日期	( $0 ) 2024-06-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.960
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Mokhtar Firdauz	Sell	0	Common Stock
2024-04-02	Flores Francisco	Sell	0	Common Stock
2024-03-18	Choong Choon Hau	Buy	54 132	Common Stock
2024-03-18	Choong Choon Hau	Sell	0	Convertible Promissory Note
2023-10-25	Natan David	Buy	16 250	Common Stock

INSIDER POWER
-84.84
Last 97 transactions
Buy: 7 283 197 \| Sell: 21 662 130

Titan Pharmaceuticals Inc 相关性

10 最正相关

10 最负相关
NETE	-0.806

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Titan Pharmaceuticals Inc 财务报表

Annual	2023
营收:	$184 000
毛利润:	$72 000.00 (39.13 %)
EPS:	$-7.41

FY	2023
营收:	$184 000
毛利润:	$72 000.00 (39.13 %)
EPS:	$-7.41

FY	2022
营收:	$60 000.00
毛利润:	$-136 000 (-226.67 %)
EPS:	$-15.15

FY	2021
营收:	$1.53M
毛利润:	$1.33M (86.96 %)
EPS:	$-0.900

Financial Reports:

No articles found.

Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.